These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17541233)

  • 1. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
    Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
    J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 7. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C; Boucheron A; Guillaume S; Koné-Paut I
    Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M; Yasuoka H; Takeuchi T
    Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.
    Yuzuriha A; Saitoh T; Koiso H; Mitsui T; Uchiumi H; Yokohama A; Handa H; Kojima M; Tsukamoto N; Karaswa M; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(3):147-50. PubMed ID: 21757886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease.
    Ebisawa K; Shimura A; Honda A; Masamoto Y; Nakahara F; Kurokawa M
    Leuk Lymphoma; 2021 Mar; 62(3):614-619. PubMed ID: 33076723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement].
    Ohno N; Fujiyama S; Ooi M; Haraguchi K; Tokunaga M; Uozumi K; Tsubouchi H
    Nihon Naika Gakkai Zasshi; 2007 May; 96(5):988-90. PubMed ID: 17564092
    [No Abstract]   [Full Text] [Related]  

  • 16. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
    Taniguchi K; Shimazaki C; Fujimoto Y; Shimura K; Uchiyama H; Matsumoto Y; Kuroda J; Horiike S; Taniwaki M
    Int J Hematol; 2009 Jul; 90(1):99-102. PubMed ID: 19554396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
    Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
    Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab.
    Venkiteshwaran A
    MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
    Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
    Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.